A study of 40 female sex workers reveals that a single daily dose of doxycycline is associated with significantly reduced STIs, primarily syphilis.
The at-home test can detect chlamydia, gonorrhea, and trichomoniasis and deliver results within 30 minutes.
Researchers found that roughly 30% of chlamydia and gonorrhea patients did not receive treatment, while only 14% and 39% received recommended antibiotics.
Researchers find a marked increase in tetracycline-resistant gonorrhea and increased colonization with tetracycline-resistant Staphylococcus aureus following the rollout of doxyPEP.
Among patients prescribed doxycycline post-exposure prophylaxis, cases of syphilis, chlamydia, and gonorrhea fell by 86.4%. 89.7%, and 54.7%, respectively.
The rate of gonorrhea cases across Europe rose by 31% in 2023 compared with 2022, and is up 321% since 2014.
Two studies in California found significant reductions in chlamydia and syphilis in the year after doxycycline post-exposure prophylaxis guidelines were released.
The number of STIs declined almost 2% from 2022 to 2023, a sign that the dramatic rise in STIs since 2011 might be leveling off.
Health officials say the STI epidemic is at a tipping point, with more federal support needed for testing and treatment.
The FDA said the test offers a private and quick testing option, along with streamlined treatment, if needed.
